Wen Baojiang, Te Liger, Bai Changsen, Jiang Wenna, Zuo Duo, Hao Qianhui, Wang Jiayi, Ren Li
Department of Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin Key Laboratory of Digestive Cancer, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Department of Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin Key Laboratory of Digestive Cancer, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
J Infect. 2024 Dec;89(6):106298. doi: 10.1016/j.jinf.2024.106298. Epub 2024 Oct 3.
China, which has the largest number of patients with primary liver cancer (PLCs), lacks data on the overall prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in PLCs. We aimed to comprehensively assess the seroprevalence of HBV and HCV among PLCs in China.
We included and pooled observational studies reporting seroprevalence of HBsAg and anti-HCV antibodies among PLCs in China by searching PubMed, Web of Science, Cochrane, Scopus, Embase, CNKI, Wanfang, and CBM. Multivariate meta-regression and subgroup analyses were used to explore sources of heterogeneity, and publication bias was assessed by funnel plots and Egger's test. PROSPERO registration number is CRD42023450382.
A total of 217 eligible studies were included in the meta-analysis. The estimated seroprevalence of HBV and HCV in PLCs was 75.09% (95% CI 73.12-77.02) and 11.82% (95% CI 9.79-14.00), respectively. After stratifying and analysing subgroups by region and study period, we found geographic differences in HBV and HCV prevalence among PLCs, with an overall increasing trend in the proportion of HBV and a decreasing trend in the proportion of HCV as well as co-infections in the last 40 years.
HBV and HCV infections still account for a high proportion of PLCs in China.
中国是原发性肝癌（PLC）患者数量最多的国家，但缺乏关于PLC中乙型肝炎病毒（HBV）和丙型肝炎病毒（HCV）总体流行率的数据。我们旨在全面评估中国PLC中HBV和HCV的血清流行率。
通过检索PubMed、Web of Science、Cochrane、Scopus、Embase、中国知网、万方和中国生物医学文献数据库，纳入并汇总了报告中国PLC中HBsAg和抗HCV抗体血清流行率的观察性研究。采用多变量meta回归和亚组分析来探索异质性来源，并通过漏斗图和Egger检验评估发表偏倚。PROSPERO注册号为CRD42023450382。
meta分析共纳入217项符合条件的研究。PLC中HBV和HCV的估计血清流行率分别为75.09%（95%CI 73.12 - 77.02）和11.82%（95%CI 9.79 - 14.00）。按地区和研究时期对亚组进行分层分析后，我们发现PLC中HBV和HCV流行率存在地理差异，在过去40年中，HBV比例总体呈上升趋势，HCV比例以及合并感染比例呈下降趋势。
在中国，HBV和HCV感染在PLC中仍占很高比例。
